{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:07:40Z","timestamp":1794888460648,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EMBL and Shionogi &amp; Co., Ltd. Osaka, Japan."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Baloxavir acid (BXA), derived from the prodrug baloxavir marboxil (BXM), potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses. In clinical trials, single doses of BXM profoundly decrease viral titers as well as alleviating influenza symptoms. Here, we characterize the impact on BXA susceptibility and replicative capacity of variant viruses detected in the post-treatment monitoring of the clinical studies. We find that the PA I38T substitution is a major pathway for reduced susceptibility to BXA, with 30- to 50-fold and 7-fold EC\n                    <jats:sub>50<\/jats:sub>\n                    changes in A and B viruses, respectively. The viruses harboring the I38T substitution show severely impaired replicative fitness in cells, and correspondingly reduced endonuclease activity\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Co-crystal structures of wild-type and I38T influenza A and B endonucleases bound to BXA show that the mutation reduces van der Waals contacts with the inhibitor. A reduced affinity to the I38T mutant is supported by the lower stability of the BXA-bound endonuclease. These mechanistic insights provide markers for future surveillance of treated populations.\n                  <\/jats:p>","DOI":"10.1038\/s41598-018-27890-4","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T06:56:02Z","timestamp":1529391362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":443,"title":["Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil"],"prefix":"10.1038","volume":"8","author":[{"given":"Shinya","family":"Omoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Speranzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Noshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeki","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Shishido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-0796","authenticated-orcid":false,"given":"Stephen","family":"Cusack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"27890_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1750-2659.2009.00073.x","volume":"3","author":"WW Thompson","year":"2009","unstructured":"Thompson, W. W. et al. Estimates of US influenza-associated deaths made using four different methods. Influenza and other respiratory viruses 3, 37\u201349, https:\/\/doi.org\/10.1111\/j.1750-2659.2009.00073.x (2009).","journal-title":"Influenza and other respiratory viruses"},{"key":"27890_CR2","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMra1002842","volume":"363","author":"LC Lambert","year":"2010","unstructured":"Lambert, L. C. & Fauci, A. S. Influenza vaccines for the future. The New England journal of medicine 363, 2036\u20132044, https:\/\/doi.org\/10.1056\/NEJMra1002842 (2010).","journal-title":"The New England journal of medicine"},{"key":"27890_CR3","doi-asserted-by":"publisher","first-page":"e0119115","DOI":"10.1371\/journal.pone.0119115","volume":"10","author":"G Dong","year":"2015","unstructured":"Dong, G. et al. Adamantane-resistant influenza a viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations. PloS one 10, e0119115, https:\/\/doi.org\/10.1371\/journal.pone.0119115 (2015).","journal-title":"PloS one"},{"key":"27890_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","volume":"283","author":"JJ Treanor","year":"2000","unstructured":"Treanor, J. J. et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. Jama 283, 1016\u20131024 (2000).","journal-title":"Jama"},{"key":"27890_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","volume":"355","author":"KG Nicholson","year":"2000","unstructured":"Nicholson, K. G. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355, 1845\u20131850 (2000).","journal-title":"Lancet"},{"key":"27890_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1086\/600383","volume":"200","author":"N Lee","year":"2009","unstructured":"Lee, N. et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. The Journal of infectious diseases 200, 492\u2013500, https:\/\/doi.org\/10.1086\/600383 (2009).","journal-title":"The Journal of infectious diseases"},{"key":"27890_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3851\/IMP1722","volume":"16","author":"N Lee","year":"2011","unstructured":"Lee, N. et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antiviral therapy 16, 237\u2013247, https:\/\/doi.org\/10.3851\/IMP1722 (2011).","journal-title":"Antiviral therapy"},{"key":"27890_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/irv.12293","volume":"9","author":"AC Hurt","year":"2015","unstructured":"Hurt, A. C., Hui, D. S., Hay, A. & Hayden, F. G. Overview of the 3rd isirv-Antiviral Group Conference\u2013advances in clinical management. Influenza and other respiratory viruses 9, 20\u201331, https:\/\/doi.org\/10.1111\/irv.12293 (2015).","journal-title":"Influenza and other respiratory viruses"},{"key":"27890_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.virusres.2017.01.013","volume":"234","author":"A Pflug","year":"2017","unstructured":"Pflug, A., Lukarska, M., Resa-Infante, P., Reich, S. & Cusack, S. Structural insights into RNA synthesis by the influenza virus transcription-replication machine. Virus research 234, 103\u2013117, https:\/\/doi.org\/10.1016\/j.virusres.2017.01.013 (2017).","journal-title":"Virus research"},{"key":"27890_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","volume":"14","author":"AJ Te Velthuis","year":"2016","unstructured":"Te Velthuis, A. J. & Fodor, E. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nature reviews. Microbiology 14, 479\u2013493, https:\/\/doi.org\/10.1038\/nrmicro.2016.87 (2016).","journal-title":"Nature reviews. Microbiology"},{"key":"27890_CR11","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1128\/JVI.79.9.5812-5818.2005","volume":"79","author":"OG Engelhardt","year":"2005","unstructured":"Engelhardt, O. G., Smith, M. & Fodor, E. Association of the influenza a virus RNA-dependent RNA polymerase with cellular RNA polymerase II. Journal of Virology 79, 5812\u20135818, https:\/\/doi.org\/10.1128\/jvi.79.9.5812-5818.2005 (2005).","journal-title":"Journal of Virology"},{"key":"27890_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature20594","volume":"541","author":"M Lukarska","year":"2017","unstructured":"Lukarska, M. et al. Structural basis of an essential interaction between influenza polymerase and Pol II CTD. Nature 541, 117\u2013121, https:\/\/doi.org\/10.1038\/nature20594 (2017).","journal-title":"Nature"},{"key":"27890_CR13","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nsmb.1421","volume":"15","author":"D Guilligay","year":"2008","unstructured":"Guilligay, D. et al. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 15, 500\u2013506 (2008).","journal-title":"Nat Struct Mol Biol"},{"key":"27890_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature07745","volume":"458","author":"A Dias","year":"2009","unstructured":"Dias, A. et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458, 914\u2013918 (2009).","journal-title":"Nature"},{"key":"27890_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nature07720","volume":"458","author":"P Yuan","year":"2009","unstructured":"Yuan, P. et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458, 909\u2013913 (2009).","journal-title":"Nature"},{"key":"27890_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14009","volume":"516","author":"S Reich","year":"2014","unstructured":"Reich, S. et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 516, 361\u2013366, https:\/\/doi.org\/10.1038\/nature14009 (2014).","journal-title":"Nature"},{"key":"27890_CR17","doi-asserted-by":"crossref","unstructured":"Pflug, A., Gaudon, S., Resa-Infante, P., Reich, S. & Cusack, S. Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors. Nucleic Acids Res In revision. (2017).","DOI":"10.1093\/nar\/gkx1210"},{"key":"27890_CR18","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1128\/JVI.73.4.3473-3476.1999","volume":"73","author":"LL Poon","year":"1999","unstructured":"Poon, L. L., Pritlove, D. C., Fodor, E. & Brownlee, G. G. Direct evidence that the poly(A) tail of influenza A virus mRNA is synthesized by reiterative copying of a U track in the virion RNA template. J Virol 73, 3473\u20133476 (1999).","journal-title":"J Virol"},{"key":"27890_CR19","doi-asserted-by":"publisher","first-page":"8915","DOI":"10.1021\/jm401369y","volume":"56","author":"S Pautus","year":"2013","unstructured":"Pautus, S. et al. New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain. Journal of medicinal chemistry 56, 8915\u20138930, https:\/\/doi.org\/10.1021\/jm401369y (2013).","journal-title":"Journal of medicinal chemistry"},{"key":"27890_CR20","doi-asserted-by":"publisher","first-page":"e1002830","DOI":"10.1371\/journal.ppat.1002830","volume":"8","author":"RM DuBois","year":"2012","unstructured":"DuBois, R. M. et al. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS pathogens 8, e1002830, https:\/\/doi.org\/10.1371\/journal.ppat.1002830 (2012).","journal-title":"PLoS pathogens"},{"key":"27890_CR21","doi-asserted-by":"publisher","first-page":"e1002831","DOI":"10.1371\/journal.ppat.1002831","volume":"8","author":"E Kowalinski","year":"2012","unstructured":"Kowalinski, E. et al. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS pathogens 8, e1002831, https:\/\/doi.org\/10.1371\/journal.ppat.1002831 (2012).","journal-title":"PLoS pathogens"},{"key":"27890_CR22","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/med.21401","volume":"36","author":"A Stevaert","year":"2016","unstructured":"Stevaert, A. & Naesens, L. The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design. Medicinal research reviews 36, 1127\u20131173, https:\/\/doi.org\/10.1002\/med.21401 (2016).","journal-title":"Medicinal research reviews"},{"key":"27890_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","volume":"149","author":"JL McKimm-Breschkin","year":"2018","unstructured":"McKimm-Breschkin, J. L. et al. Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antiviral research 149, 118\u2013142, https:\/\/doi.org\/10.1016\/j.antiviral.2017.11.013 (2018).","journal-title":"Antiviral research"},{"key":"27890_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Y Furuta","year":"2002","unstructured":"Furuta, Y. et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial agents and chemotherapy 46, 977\u2013981 (2002).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"27890_CR25","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AAC.04623-14","volume":"59","author":"RA Byrn","year":"2015","unstructured":"Byrn, R. A. et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrobial agents and chemotherapy 59, 1569\u20131582, https:\/\/doi.org\/10.1128\/AAC.04623-14 (2015).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"27890_CR26","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","volume":"57","author":"MP Clark","year":"2014","unstructured":"Clark, M. P. et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. Journal of medicinal chemistry 57, 6668\u20136678, https:\/\/doi.org\/10.1021\/jm5007275 (2014).","journal-title":"Journal of medicinal chemistry"},{"key":"27890_CR27","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1021\/jm400645w","volume":"56","author":"BA Johns","year":"2013","unstructured":"Johns, B. A. et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S\/GSK1349572) and (S\/GSK1265744). Journal of medicinal chemistry 56, 5901\u20135916, https:\/\/doi.org\/10.1021\/jm400645w (2013).","journal-title":"Journal of medicinal chemistry"},{"key":"27890_CR28","unstructured":"Uehara, T., Shishido, T. & Ishibashi, T. S-033188, a small molecule inhibitor of Cap-dependent endonuclease of influenza A and Bvirus, leads to rapid and profound viral load reduction. Options IX for the Control of Influenza (2016)."},{"key":"27890_CR29","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1128\/JVI.77.15.8418-8425.2003","volume":"77","author":"M Matrosovich","year":"2003","unstructured":"Matrosovich, M., Matrosovich, T., Carr, J., Roberts, N. A. & Klenk, H. D. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 77, 8418\u20138425 (2003).","journal-title":"J Virol"},{"key":"27890_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.vaccine.2016.11.060","volume":"35","author":"CA van Baalen","year":"2017","unstructured":"van Baalen, C. A. et al. ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. Vaccine 35, 46\u201352, https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.060 (2017).","journal-title":"Vaccine"},{"key":"27890_CR31","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1073\/pnas.1519772113","volume":"113","author":"MS Song","year":"2016","unstructured":"Song, M. S. et al. Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor. Proceedings of the National Academy of Sciences of the United States of America 113, 3669\u20133674, https:\/\/doi.org\/10.1073\/pnas.1519772113 (2016).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"27890_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.molcel.2015.11.016","volume":"61","author":"E Thierry","year":"2016","unstructured":"Thierry, E. et al. Influenza Polymerase Can Adopt an Alternative Configuration Involving a Radical Repacking of PB2 Domains. Molecular cell 61, 125\u2013137, https:\/\/doi.org\/10.1016\/j.molcel.2015.11.016 (2016).","journal-title":"Molecular cell"},{"key":"27890_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ab.2006.07.027","volume":"357","author":"UB Ericsson","year":"2006","unstructured":"Ericsson, U. B., Hallberg, B. M., Detitta, G. T., Dekker, N. & Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. Analytical biochemistry 357, 289\u2013298, https:\/\/doi.org\/10.1016\/j.ab.2006.07.027 (2006).","journal-title":"Analytical biochemistry"},{"key":"27890_CR34","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1128\/JVI.00995-10","volume":"84","author":"T Crepin","year":"2010","unstructured":"Crepin, T. et al. Mutational and metal binding analysis of the endonuclease domain of the influenza virus polymerase PA subunit. J Virol 84, 9096\u20139104, https:\/\/doi.org\/10.1128\/JVI.00995-10 (2010).","journal-title":"J Virol"},{"key":"27890_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.antiviral.2014.07.001","volume":"110","author":"A Meijer","year":"2014","unstructured":"Meijer, A. et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral research 110, 31\u201341, https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.001 (2014).","journal-title":"Antiviral research"},{"key":"27890_CR36","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1128\/JVI.02681-13","volume":"88","author":"Y Abed","year":"2014","unstructured":"Abed, Y., Pizzorno, A., Bouhy, X., Rheaume, C. & Boivin, G. Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. J Virol 88, 1652\u20131658, https:\/\/doi.org\/10.1128\/JVI.02681-13 (2014).","journal-title":"J Virol"},{"key":"27890_CR37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1128\/JVI.01658-12","volume":"87","author":"NC Wu","year":"2013","unstructured":"Wu, N. C. et al. Systematic identification of H274Y compensatory mutations in influenza A virus neuraminidase by high-throughput screening. J Virol 87, 1193\u20131199, https:\/\/doi.org\/10.1128\/JVI.01658-12 (2013).","journal-title":"J Virol"},{"key":"27890_CR38","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1073\/pnas.100133697","volume":"97","author":"E Hoffmann","year":"2000","unstructured":"Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G. & Webster, R. G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proceedings of the National Academy of Sciences of the United States of America 97, 6108\u20136113, https:\/\/doi.org\/10.1073\/pnas.100133697 (2000).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"27890_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-62703-691-7_13","volume":"1091","author":"V Mariaule","year":"2014","unstructured":"Mariaule, V., Dupeux, F. & Marquez, J. A. Estimation of crystallization likelihood through a fluorimetric thermal stability assay. Methods in molecular biology 1091, 189\u2013195, https:\/\/doi.org\/10.1007\/978-1-62703-691-7_13 (2014).","journal-title":"Methods in molecular biology"},{"key":"27890_CR40","doi-asserted-by":"publisher","unstructured":"Kabsch, W. X. Acta crystallographica. Section D, Biological crystallography 66, 125\u2013132, https:\/\/doi.org\/10.1107\/S0907444909047337 (2010).","DOI":"10.1107\/S0907444909047337"},{"key":"27890_CR41","doi-asserted-by":"publisher","unstructured":"Collaborative Computational Project, N. TheCCP4 suite: programs for protein crystallography. Acta crystallographica. Section D, Biological crystallography 50, 760\u2013763, https:\/\/doi.org\/10.1107\/S0907444994003112 (1994).","DOI":"10.1107\/S0907444994003112"},{"key":"27890_CR42","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. Journal of applied crystallography 40, 658\u2013674, https:\/\/doi.org\/10.1107\/S0021889807021206 (2007).","journal-title":"Journal of applied crystallography"},{"key":"27890_CR43","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta crystallographica. Section D, Biological crystallography 68, 352\u2013367, https:\/\/doi.org\/10.1107\/S0907444912001308 (2012).","journal-title":"Acta crystallographica. Section D, Biological crystallography"},{"key":"27890_CR44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta crystallographica. Section D, Biological crystallography 53, 240\u2013255, https:\/\/doi.org\/10.1107\/S0907444996012255 (1997).","journal-title":"Acta crystallographica. Section D, Biological crystallography"},{"key":"27890_CR45","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta crystallographica. Section D, Biological crystallography 66, 486\u2013501, https:\/\/doi.org\/10.1107\/S0907444910007493 (2010).","journal-title":"Acta crystallographica. Section D, Biological crystallography"},{"key":"27890_CR46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta crystallographica. Section D, Biological crystallography 66, 12\u201321, https:\/\/doi.org\/10.1107\/S0907444909042073 (2010).","journal-title":"Acta crystallographica. Section D, Biological crystallography"},{"key":"27890_CR47","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.str.2011.08.006","volume":"19","author":"RJ Read","year":"2011","unstructured":"Read, R. J. et al. A new generation of crystallographic validation tools for the protein data bank. Structure 19, 1395\u20131412, https:\/\/doi.org\/10.1016\/j.str.2011.08.006 (2011).","journal-title":"Structure"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27890-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:42:09Z","timestamp":1671586929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27890-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["27890"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-27890-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors, except V.S. and S.C., were employees of Shionogi & Co, Ltd. in Osaka, Japan. The results in the paper were partially generated by the funding from Shionogi & Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9633"}}